The FDA approved pimicotinib for tenosynovial giant cell tumor, accepted a gedatolisib filing in advanced breast cancer, and more.
|Podcasts|May 15, 2019
Examining Key Breast Cancer Updates in Chicago
Author(s)Onclive Team
We traveled to Chicago, Illinois, for a State of the Science Summit™ on Breast Cancer, where faculty provided a comprehensive look into present and potentially future standards of care in early-stage and advanced breast cancer subtypes.
Advertisement
We recently traveled to Chicago, Illinois, for a State of the Science Summit™ on Breast Cancer. During the meeting, the faculty provided a comprehensive look into present and potentially future standards of care in early-stage and advanced breast cancer subtypes.
Advertisement
Related to this article
Serial amino acid PET flagged responses earlier than MRI in IDH-mutant glioma treated with vorasidenib, interim data show.
Longer mirdametinib treatment increased confirmed and deep responses as treatment-related adverse effects declined in neurofibromatosis type 1 tumors.
Patrick Forde, MD, MBBCh, details how chemoimmunotherapy, pathologic response, and targeted therapy are reshaping resectable NSCLC care.
Long-term data show that plixorafenib yielded durable responses and no cumulative adverse effects in BRAF-altered primary central nervous system tumors.
The FDA approved durvalumab plus enfortumab vedotin for cisplatin-ineligible muscle-invasive bladder cancer.
UCSF experts will present key research at the 31st Society for Neuro-Oncology Annual Meeting.
The filing is supported by phase 3 REZILIENT3 data showing a median PFS of 14.5 vs 8.5 months with zipalertinib plus chemotherapy vs chemotherapy.
Advertisement
Advertisement
Trending on OncLive
1
Dr Gleave on Selecting Patients for Perioperative Therapy in High-Risk Prostate Cancer
2
Vorasidenib Elicits Early Metabolic Responses in IDH-Mutant Glioma
3
Mirdametinib Deepens Responses in NF1-Associated Plexiform Neurofibroma
4
Cross Currents: New Frontiers in ADC Therapy for Breast Cancer
5